Alloy Therapeutics has appointed Christian Cobaugh, Ph.D., as Chief Executive Officer of Alloy Genetic Medicines.

Understanding why cancer cells rely on specific genes is critical for designing effective targeted therapies. A new study ...

Zebrafish (Danio Rerio) have emerged as a powerful bioengineering platform for next-generation drug discovery, offering an unparalleled combination of ...

Cathie Wood is making a massive bet on gene editing, pouring $5.4 billion into companies like Beam Therapeutics while selling ...

By editing thousands of genes in mouse stem cells, the scientists identified a list of over 300 that are crucial for neural differentiation.

In the latest close session, CRISPR Therapeutics AG (CRSP) was up +2.58% at $55.16. This change outpaced the S&P 500's 0.64% gain on the day. Elsewhere, the Dow saw an upswing of 1.23%, while the tech ...

Since 2019, three disease-specific therapies have been approved to treat patients with ATTR-CM. The first was Pfizer’s Vyndamax (tafamidis) in May 2019, which was approved for both wild type and ...

Tiny, sun-powered organisms found in freshwater pools could soon fuel Hawaiʻi's sustainable future. Researchers at the ...

The firm plans to enroll US patients into the trial of GEB-101 in the second quarter, having launched an investigator-initiated trial in China.

The US Food and Drug Administration (FDA) has cleared GenEditBio Limited’s Investigational New Drug (IND) application to ...

A live webcast of the presentation will be available on the "Events & Presentations" page in the Investors section of the ...

Cathie Wood’s latest moves entering 2026 focused on early-stage biotechnology firms while cutting exposure to consumer technology, diagnostics and space tech companies.